Skip to main content
. 2020 Jan 17;12(1):228. doi: 10.3390/cancers12010228

Figure 7.

Figure 7

Anti-tumor efficacy of OTS-412, with or without ganciclovir (GCV), in two HCT 116 tumor-bearing mouse models. (A) (Study STG) Tumor volume measured from day 0 to day 12, post single-dose injection of saline, OTS-412 (day 0, intratumoral [IT], 1 × 106 PFU), or OTS-412 + GCV (day 0, IT, 1 × 106 PFU + once/day, day -3 to 11, intraperitoneal [IP], 25 mg/kg, respectively). ** p = 0.003, OTS-412 vs. Saline; *** p < 0.001, OTS-412 + GCV vs. Saline; P values were calculated using independent t-tests. (B) (Study STG) Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay shows cancer cell apoptosis in one representative tumor mass from each treatment group in the abovementioned single-dose study; red signal represents apoptotic cancer cells and blue signal represents cell nuclei. The histogram shows the quantification of apoptosis in tumor tissue, which was not significantly different (p = 0.13). (C) (Study MVG) Tumor volume measured from day 0 to day 21, post multiple-dose saline injection, OTS-412 (on day 0, 3, 7, 10, and 14, IP, 1 × 108 PFU), or OTS-412 + GCV (0, 3, 7, 10, and 14, IP, 1 × 108 PFU + once/day, day 0 to 20, IP, 50 mg/kg, respectively). Scale bar: 100 µm.